Daily Ards Research Analysis
Three ARDS-focused studies advance early diagnosis and mechanism-informed stratification, and propose microbiome-modulating therapy. A prospective ICU cohort identifies BALF histone H3K18 lactylation as an independent predictor of sepsis-related ARDS, while a transcriptomic study defines lactylation-based phenotypes with six candidate biomarkers; a multi-omics rat study shows fecal microbiota transplantation ameliorates LPS-induced lung injury.
Summary
Three ARDS-focused studies advance early diagnosis and mechanism-informed stratification, and propose microbiome-modulating therapy. A prospective ICU cohort identifies BALF histone H3K18 lactylation as an independent predictor of sepsis-related ARDS, while a transcriptomic study defines lactylation-based phenotypes with six candidate biomarkers; a multi-omics rat study shows fecal microbiota transplantation ameliorates LPS-induced lung injury.
Research Themes
- Epigenetic lactylation biomarkers for sepsis-related ARDS
- Mechanism-informed phenotyping and biomarker discovery
- Gut–lung axis and microbiome-based therapy in ARDS
Selected Articles
1. PREDICTIVE VALUE OF H3K18 LACTYLATION FOR EARLY DETECTION AND PROGNOSIS OF SEPSIS-RELATED ACUTE RESPIRATORY DISTRESS SYNDROME: A PROSPECTIVE OBSERVATIONAL CLINICAL STUDY.
In a prospective ICU cohort of 91 septic patients, BALF histone H3K18 lactylation was higher in those who developed ARDS, independently predicted ARDS risk, and correlated with systemic inflammation and severity scores. Diagnostic performance was strong (AUC 0.804) and improved when combined with SOFA (AUC 0.830); day-3 rises associated with mortality.
Impact: Introduces a mechanistically grounded, BALF-based epigenetic biomarker with strong diagnostic performance for sepsis-related ARDS. Prospective design and integration with SOFA suggest near-term translational potential.
Clinical Implications: H3K18la measurement in BALF could support early ARDS identification and risk stratification in septic ICU patients, guiding monitoring intensity and enrollment into trials of targeted therapies.
Key Findings
- BALF H3K18la levels were significantly higher in sepsis-related ARDS versus non-ARDS and controls (P < 0.05).
- H3K18la correlated positively with lactate, IL-6, TNF-α, APACHE II, and SOFA scores (P < 0.01).
- H3K18la independently predicted ARDS development with AUC 0.804; combined with SOFA, AUC improved to 0.830 (sensitivity 88.9%, specificity 67.3%).
- Day-3 BALF H3K18la increased significantly in the mortality group, indicating prognostic value.
Methodological Strengths
- Prospective ICU cohort with standardized BALF sampling on day 1 (and day 3 if ventilated).
- Multivariable logistic regression and ROC analysis with clinically relevant comparators (SOFA).
Limitations
- Single-center, moderate sample size (N=91) limits generalizability.
- BALF sampling may not be feasible in all patients and lacks external validation.
Future Directions: External validation across centers, development of blood-based surrogates, and integration into multimodal risk models to guide early interventions.
Background: This study aimed to investigate the predictive value of histone H3 lysine 18 lactylation (H3K18la) for the early identification and prognosis of sepsis-related acute respiratory distress syndrome (ARDS). Methods: This prospective observational study included patients with sepsis admitted to the intensive care unit (ICU) between March 2023 and September 2024. The patients were divided into two groups: the sepsis with ARDS group and the sepsis without ARDS group. Clinical data were collected within 24 h of ICU admission. Bronchoalveolar lavage fluid (BALF) samples were obtained on day 1 for all participants, and a second BALF sample was collected on day 3 from patients requiring continued mechanical ventilation. Results: In total, 91 sepsis patients were enrolled in the study: 36 with ARDS and 55 without ARDS. H3K18la levels in BALF were significantly higher in the sepsis-related ARDS group than in the non-ARDS group and the control group ( P < 0.05). Elevated H3K18la levels were positively correlated with inflammatory markers (lactate, IL-6, and TNF-α), Acute Physiology and Chronic Health Evaluation II scores, and Sequential Organ Failure Assessment scores ( P < 0.01). Logistic regression analysis revealed that H3K18la was an independent predictor of ARDS development ( P < 0.05), and ROC curve analysis revealed that H3K18la had high diagnostic accuracy (AUC = 0.804). Combining H3K18la with the Sequential Organ Failure Assessment score further improved diagnostic performance (AUC = 0.830, sensitivity = 88.9%, specificity = 67.3%). Furthermore, H3K18la levels significantly increased on day 3 in the mortality group. Conclusion: H3K18la is a promising biomarker for the early identification and prognostic prediction of sepsis-related ARDS.
2. Characterization of lactylation-based phenotypes and molecular biomarkers in sepsis-associated acute respiratory distress syndrome.
Transcriptomic analysis of sepsis-associated ARDS delineated low- and high-lactylation phenotypes with distinct immune and pathway signatures. High-lactylation status associated with longer hospital stay, higher mortality, and differential predicted drug responses; six biomarkers (ALDOB, CCT5, EP300, PFKP, PPIA, SIRT1) robustly discriminated phenotypes.
Impact: Defines mechanism-linked phenotypes and candidate biomarkers that enable risk stratification and could inform precision trials in sepsis-related ARDS.
Clinical Implications: Lactylation-based phenotyping may guide targeted therapy selection and prognosis; the six-gene panel could underpin future diagnostic assays pending validation.
Key Findings
- Identified low- and high-lactylation activity phenotypes in sepsis-associated ARDS with significant heterogeneity.
- High-lactylation phenotype associated with longer hospital stay and higher mortality.
- Defined distinct KEGG pathways, immune cell infiltration patterns, and predicted drug sensitivities across phenotypes.
- Six biomarkers (ALDOB, CCT5, EP300, PFKP, PPIA, SIRT1) discriminated phenotypes and correlated with immune cell populations.
Methodological Strengths
- Integration of clinical outcomes with blood transcriptomics and multi-analytic pipelines (KEGG, immune deconvolution, drug sensitivity prediction).
- Robust feature selection using four independent machine learning models and intersection of signature genes.
Limitations
- Retrospective computational analysis without external validation cohort.
- Blood-based signatures may not fully reflect lung compartment biology; causality cannot be inferred.
Future Directions: Prospective validation of the six-gene panel, integration with proteomics/metabolomics, and adaptive trials testing phenotype-guided therapies.
Sepsis-associated acute respiratory distress syndrome (ARDS) is a heterogeneous disease with high morbidity and mortality. Lactylation plays a crucial role in sepsis and sepsis-induced lung injury. This study aimed to identify distinct lactylation-based phenotypes in patients with sepsis-associated ARDS and determine relevant molecular biomarkers. We analyzed blood transcriptome and clinical data from patients with sepsis-associated ARDS and calculated the lactylation activity. KEGG pathway analysis, drug sensitivity prediction, and immune cell infiltration analysis were performed. Candidate molecular biomarkers were identified by intersecting the feature genes extracted from four machine learning models. Lactylation activity showed significant heterogeneity among patients with sepsis-associated ARDS, which enabled the classification into low- and high-lactylation activity phenotypes. Patients with high-lactylation experienced longer hospital stays and higher mortality rates, as well as distinct signaling pathways, drug responses, and circulating immune cell abundances. Six key markers (ALDOB, CCT5, EP300, PFKP, PPIA, and SIRT1) were identified to differentiate the two lactylation activity phenotypes, all significantly correlated with circulating immune cell populations. This study revealed significant heterogeneity in lactylation activity phenotypes among patients with sepsis-associated ARDS and identified potential biomarkers to facilitate the application of these phenotypes in clinical practice.
3. Impact of fecal microbiota transplantation on lung function and gut microbiome in an ARDS rat model: A multi-omics analysis including 16S rRNA sequencing, metabolomics, and transcriptomics.
In an LPS-induced ARDS rat model with antibiotic pretreatment, fecal microbiota transplantation attenuated lung injury and improved oxygenation. Multi-omics profiling showed that FMT reshaped gut microbiota and modulated metabolic and immune pathways, supporting the gut–lung axis as a therapeutic target.
Impact: Provides preclinical mechanistic evidence linking microbiome modulation to improved lung function in ARDS and employs comprehensive multi-omics to map pathways.
Clinical Implications: While preclinical, findings justify exploration of microbiome-based adjunctive therapies (e.g., FMT or defined consortia) in ARDS with careful safety evaluation.
Key Findings
- FMT reduced histopathologic lung injury and improved pulmonary function (improved arterial oxygenation) in LPS-induced ARDS rats.
- 16S rRNA sequencing showed FMT reshaped gut microbial communities after antibiotic depletion.
- Metabolomics and lung transcriptomics indicated modulation of metabolic and immune pathways consistent with improved outcomes.
Methodological Strengths
- Multi-omics approach (16S, metabolomics, transcriptomics) linking microbiome changes to lung outcomes.
- Controlled experimental design with antibiotic depletion and LPS-induced injury before FMT.
Limitations
- Preclinical animal model; translational relevance requires human studies.
- Antibiotic pretreatment and LPS injury may not recapitulate all ARDS etiologies.
Future Directions: Define microbial taxa/functions responsible for benefit, test safety and efficacy in early-phase clinical studies, and compare FMT with defined microbial consortia.
OBJECTIVE: Acute respiratory distress syndrome (ARDS) is a severe pulmonary condition characterized by inflammation and lung damage, frequently resulting in poor clinical outcomes. Recent studies suggest that the gut-lung axis, mediated by gut microbiota, is critical in ARDS progression. This study investigates the therapeutic potential of fecal microbiota transplantation (FMT) in an ARDS rat model ( INTRODUCTION: The pathogenesis of ARDS involves complex interactions between the lungs and gut, with microbiota playing a key role. Understanding the effects of FMT on lung function and gut microbiota may provide new therapeutic strategies for ARDS management. METHODS: Sprague-Dawley rats were pre-treated with a broad-spectrum antibiotic cocktail to create a germ-free state and subsequently exposed to intranasal lipopolysaccharide to induce ARDS. The rats then received FMT treatment. Lung samples were analyzed using histopathology and transcriptomics. Fecal samples were analyzed using 16S rRNA sequencing and metabolomics. RESULTS: FMT treatment significantly reduced lung injury and improved pulmonary function, as evidenced by increased partial pressure of arterial oxygen (PaO CONCLUSION: These findings indicate that FMT may exert its beneficial effects in ARDS by modulating the gut microbiota and enhancing metabolic and immune responses. However, given that this study remains in the preclinical stage, further validation in clinical studies is necessary before considering clinical application.